Purported Benefits, Side Effects & More


Purported Benefits, Side Effects & More

Common Names

  • Coneflower; purple coneflower
  • Black Sampson; Sampson root
  • Sonnenhut
  • Igelkopfwurzel

For Patients & Caregivers

Tell your healthcare providers about any dietary supplements you’re taking, such as herbs, vitamins, minerals, and natural or home remedies. This will help them manage your care and keep you safe.

What is it?

Echinacea is a plant that belongs to the sunflower family. It’s commonly used in herbal medicine. Echinacea also comes as capsules, pills, tablets, or liquid extracts.

What are the potential uses and benefits?

Echinacea is used to:

  • Prevent and treat common cold
  • Strengthen your immune system
  • Prevent and treat influenza (the flu)
  • Heal wounds

Echinacea also has other uses that haven’t been studied by doctors to see if they work.

It’s generally safe to use echinacea. But talk with your healthcare providers before taking echinacea supplements. They can have higher amounts of the herb, and can also interact with some medications and affect how they work.

For more information, read the “What else do I need to know?” section below.

What are the side effects?

Side effects of using echinacea may include:

  • Headache
  • Dizziness
  • Nausea (feeling like you’re going to throw up)
  • Constipation (having fewer bowel movements than usual)
  • Mild stomach pain
  • Skin rash
What else do I need to know?
  • Talk to your healthcare provider if you’re taking immunosuppressants like tacrolimus (Prograf®) or cyclosporine (Gengraf®, Neoral® or Sandimmune®). Echinacea may make these medications less effective.
  • Talk to your healthcare provider if you’re taking etoposide (Toposar®, VePesid®, Etopophos®, VP-16). Echinacea can decrease your blood platelet count.
  • Talk to your healthcare provider before taking echinacea in any form if you’re pregnant or breastfeeding. It may not be safe for you.

For Healthcare Professionals

Brand Name
Echinagard®, Echinacin®, Echinaforce® Hotdrink
Scientific Name
Echinacea purpurea, Echinacea angustifolia, Echinacea pallida
Clinical Summary

The genus Echinacea belongs to the family Compositae, commonly referred to as the sunflower family. Of the known species, E. purpurea, E. angustifolia, and E. pallida are commonly used in herbal medicine. Extracts derived from the root and aerial parts are widely used in Europe and the United States as nonspecific immunostimulants and to prevent or treat the common cold and influenza. However, natural products differ greatly in composition (26), mainly due to the use of different species, variable plant materials or extraction methods, and the addition of other components. Preclinical studies suggest immunostimulatory and anti-inflammatory effects (27). A standardized echinacea preparation inactivated influenza viruses (28) and may improve respiratory activity (2) (3). In animal models, echinacea stimulated erythropoiesis, increased blood-oxygen transport (29) (30), produced anxiolytic effects (31), and exhibited wound-healing properties (32) (33) (34).

Clinical data indicate that echinacea is ineffective in preventing the common cold caused by rhinoviruses (4) or in treating upper respiratory infections (5) (6) (16) but positive findings were reported with higher doses (70). Studies of its ability to reduce incidence and duration of the common cold yielded mixed results (7) (8) (9) (10) (22) (35) (36). Other analyses do not indicate any benefits for treating colds, and weak evidence for a prophylactic benefit (26) (37), but a large randomized trial found an echinacea formulation to be as effective as oseltamivir for influenza, and with fewer adverse events in the echinacea group (38). In a review of 17 clinical trials involving 3,363 participants, echinacea supplements were found to affect reductions in pro-inflammatory cytokines that play a role in the progression of cytokine storm and acute respiratory distress syndrome (ARDS) (68). Echinacea was also reported useful in preventing respiratory tract infections and reducing associated antibiotic usage in children (71).
Small studies have shown that a standardized echinacea root extract has immunomodulating activity (39); an echinacea/sage spray was useful in treating acute sore throats (17); and a formula containing dry root extracts of Echinacea purpurea and Echinacea angustifolia may be useful as an adjuvant therapy for decreasing relapse incidence in patients treated for genital condylomatosis (67) and in those with cervical low-grade squamous intraepithelial lesions (72). Data on anxiolytic effects are mixed (69) (73) but findings on improving or enhancing athletic performance are mixed (40) (41). A topical echinacea extract was reported effective in alleviating symptoms associated with atopic eczema (63). Echinacea may also have anticancer potential evidenced by the cytotoxic effects exerted by an extract and a major compound, cichoric acid, in human colon cancer cells (42).

Some studies suggest that echinacea could decrease plasma levels, affect therapeutic efficacy, or cause adverse effects with some anticancer drugs (25) (43). In HIV-infected patients, co-administration with etravirine was found to be safe and well tolerated (44). In a large population-based study, use of echinacea was associated with a slight increase in diastolic blood pressure (45). There is insufficient evidence regarding the efficacy and safety of echinacea during pregnancy (46).

Purported Uses and Benefits
  • Common cold
  • Immunostimulation
  • Viral infections
  • Wound healing
Mechanism of Action

Echinacea’s active constituents include cichoric and caftaric acids, polysaccharides, and alkylamides (47). Immune-modulating effects of a standardized echinacea root extract include upregulation of interleukin (IL)-2 and IL-8 and downregulation of pro-inflammatory cytokines tumor necrosis factor (TNF)-alpha and IL-6 (39). Immunemodulation by alkylamides occurs through binding to human cannabinoid receptors 1 and 2, and by inhibiting TNF-alpha (48). Alkylamides may also be responsible for anti-inflammatory effects (27). Although echinacea does not appear to have significant ergogenic or anabolizing effects, it appears to enhance the immune system and decrease oxidative damage (49).

In vitro and in vivo, echinacea extracts were shown to stimulate phagocytosis, enhance mobility of leukocytes, stimulate TNF and IL-1 secretion from macrophages and lymphocytes, and improve respiratory activity (2) (3). However, their effects on innate immunity such as phagocytosis could not be confirmed, and showed only minimal effects on tumor progression, although echinacea did stimulate natural killer cell activity (50). Other studies suggest that bacterial components of echinacea are responsible for immune benefits, as total bacterial load differences and content of bacterial lipopolysaccharides within echinacea samples have correlated with NF-kappaB activation in THP-1 cells (51).

In human colon cancer cells, cichoric acid decreased telomerase activity and induced apoptosis via DNA fragmentation, caspase-9 activation, poly-ADP-ribose polymerase (PARP) cleavage and beta-catenin downregulation (42). Differential effects of echinacea on intestinal and hepatic CYP3A activities may be due to systemic unavailability of locally-acting constituents that inhibit CYP3A, or rapid absorption of these constituents that limits intestinal exposure and CYP3A induction, or a systemically-formed constituent metabolite that is capable of inducing hepatic but not intestinal CYP3A (52).

  • Patients undergoing chemotherapy should use caution with echinacea, as it may reduce the efficacy of some anticancer medications or cause adverse effects (25) (43) (53).
  • Patients with allergies or asthma should exercise caution with echinacea, as allergic reactions have been reported (54).
  • Patients undergoing blepharoplasty (eyelid surgery), should avoid echinacea because of added increased risk of dry eye syndrome (55).
Adverse Reactions

Common: Headache, dizziness, nausea, constipation, gastrointestinal upset, rash (5) (11) (12) (54)
Rare: Dermatitis, anaphylaxis (13) (54)

Case Reports – Oral 
Profound thrombocytopenia: In a 61-year-old man with nonsmall cell lung cancer who was concurrently taking echinacea while receiving chemoradiation with cisplatin and etoposide (25).
Severe thrombotic thrombocytopenic purpura (TTP): In a 32-year-old man following ingestion of echinacea to alleviate upper respiratory tract infection symptoms. TTP resolved after treatment for a month (18).
Pemphigus vulgaris exacerbation: In a 55-year-old man with a history of the condition which was controlled with immunosuppressants. Exacerbation was linked to consumption of echinacea, and only partial remission was regained after he was treated again with immunosuppressants (19).
Asymptomatic leukopenia: In a 51-year-old woman following chronic use of echinacea. Her white blood cell count returned to normal levels 7 months after discontinuing echinacea supplements (20).
Severe acute hepatitis: In a 45-year-old man who complained of fatigue and jaundice lasting one week, linked to the ingestion of daily high doses of echinacea used to strengthen his immune system after catching the cold (23).
Severe acute liver failure: In a 2-year-old girl, likely secondary to echinacea toxicity (56).
Hypereosinophilia: In a 58-year-old man following echinacea consumption, with symptoms improving after discontinuing echinacea (24).
Bilateral central facial palsy and severe quadriparesis: In a 25 year-old male after taking herbal drugs (containing echinacea and many other herbal ingredients) for two weeks. Symptoms improved after conventional treatment (64).
Acute cholestatic hepatitis: In a 41-year-old man following consumption of echinacea to strengthen immune system. His condition improved after discontinuing its use (65).

Case Reports – Topical 
Eye irritation and conjunctivitis: 7 reports following use of topical echinacea were received by The National Registry of Drug-Induced Ocular Side Effects. Symptoms resolved after discontinuing echinacea (21).

Herb-Drug Interactions

Cytochrome P450 substrates: Echinacea inhibits CYP3A4 (14) (43) and CYP2C8 (66) and can affect the intracellular concentration of drugs metabolized by this enzyme. Clinical relevance is not known.

Cytochrome P3A or CYP1A2 substrate drugs: Caution should be used when echinacea is coadministered with drugs dependent on CYP3A or CYP1A2 for their elimination (57). Clinical relevance is not known.

Tamoxifen: In vitro studies suggest concurrent echinacea use may result in subtherapeutic systemic exposure of prodrugs such as tamoxifen, reducing their efficacy (43). Clinical relevance is not known.

Docetaxel: In a study of cancer patients receiving docetaxel, echinacea at the recommended dosage did not significantly alter docetaxel pharmacokinetics (58) (59).

Etoposide: Echinacea caused profound thrombocytopenia in a patient receiving etoposide, likely due to the inhibition of CYP3A4 (25).

P-glycoprotein (P-gp) substrate drugs: In vitro, echinacea has been shown to inhibit P-gp activity (60), but the clinical significance of this is uncertain as echinacea supplementation in humans did not affect digoxin pharmacokinetics (61).

Oseltamivir: In vitro, echinacea reduced the formation of the active drug and may therefore reduce efficacy, but clinical significance is as yet undetermined (62).

Immunosuppressants: Echinacea may antagonize the effects of immunosuppressants (19). Clinical relevance is not known.

Dosage (OneMSK Only)
  1. Gilroy CM, Steiner JF, Byers T, Shapiro H, Georgian W. Echinacea and truth in labeling. Arch Intern Med 2003;163:699-704.
  2. Melchart D, Clemm C, Weber B, et al. Polysaccharides isolated from Echinacea purpurea herba cell cultures to counteract undesired effects of chemotherapy-a pilot study. Phytotherapy Res 2002;16:138-42.
  3. Groom SN, Johns T, Oldfield PR. The potency of immunomodulatory herbs may be primarily dependent upon macrophage activation. J Med Food. Mar 2007;10(1):73-79.
  4. Turner RB, Bauer R, Woelkart K, Hulsey TC, Gangemi JD. An Evaluation of Echinacea angustifolia in Experimental Rhinovirus Infections. N Engl J Med. 2005;353(4):341-348.
  5. Taylor JA, Weber W, Standish L, et al. Efficacy and Safety of Echinacea in Treating Upper Respiratory Tract Infections in Children: A Randomized Controlled Trial. JAMA 2003;290:2824-30.
  6. Yale SH, Liu K. Echinacea purpurea Therapy for the Treatment of the Common Cold. Arch Intern Med. 2004;164:1237-1241.
  7. Shah SA, Sander S, White CM, Rinaldi M, Coleman CI. Evaluation of echinacea for the prevention and treatment of the common cold: a meta-analysis. Lancet Infect Dis 2007;7(7):473-80.
  8. Schulten B, Bulitta M, Ballering-Bruhl B, Koster U, Schafer M. Efficacy of Echinacea purpurea in patients with a common cold. A placebo-controlled, randomized, double-blind clinical trial. Arzneimittelforschung 2001;51:563-8.
  9. Melchart D, Linde K, Fischer P, Kaesmayr J. Echinacea for preventing and treating the common cold. Cochrane Database Syst Rev 2001;4:1-15.
  10. Linde K, Barrett B, Wolkart K, Bauer R, Melchart D. Echinacea for preventing and treating the common cold. Cochrane Database Syst Rev. 2006;(1):CD000530.
  11. Giles JT, Palat CT, 3rd, Chien SH, Chang ZG, Kennedy DT. Evaluation of echinacea for treatment of the common cold. Pharmacotherapy 2000;20:690-7.
  12. Grimm W, Muller HH. A randomized controlled trial of the effect of fluid extract of Echinacea purpurea on the incidence and severity of colds and respiratory infections. Am J Med 1999;106:138-43.
  13. Newall C, et al. Herbal Medicines: A Guide for Health-care Professionals. 1st ed. London: Pharmaceutical Press; 1996.
  14. Scott GN, Elmer GW. Update on natural product-drug interactions. Am J Health-Syst Pharm 2002;59:339-47.
  15. Brinker F. Herb Contraindications and Drug Interactions. 3rd ed. Sandy (OR): Eclectic Medical Publications; 2001.
  16. O’Neil J, Hughes S, Lourie A, Zweifler J. Effects of echinacea on the frequency of upper respiratory tract symptoms: a randomized, double-blind, placebo-controlled trial. Ann Allergy Asthma Immunol. 2008 Apr;100(4):384-8.
  17. Schapowal A, Berger D, Klein P, Suter A. Echinacea/sage or chlorhexidine/lidocaine for treating acute sore throats: a randomized double-blind trial. Eur J Med Res. 2009 Sep 1;14(9):406-12.
  18. Liatsos G, Elefsiniotis I, Todorova R, Moulakakis A. Severe thrombotic thrombocytopenic purpura (TTP) induced or exacerbated by the immunostimulatory herb Echinacea. Am J Hematol. 2006 Mar;81(3):224.
  19. Lee AN, Werth VP. Activation of autoimmunity following use of immunostimulatory herbal supplements. Arch Dermatol. 2004 Jun;140(6):723-7.
  20. Kemp DE, Franco KN. Possible leukopenia associated with long-term use of echinacea. J Am Board Fam Pract. 2002 Sep-Oct;15(5):417-9.
  21. Fraunfelder FW. Ocular side effects from herbal medicines and nutritional supplements. Am J Ophthalmol. 2004 Oct;138(4):639-47.
  22. Barrett B, Brown R, Rakel D, et al. Echinacea for treating the common cold: a randomized trial. Ann Intern Med. 2010 Dec 21;153(12):769-77.
  23. Kocaman O, Hulagu S, Senturk O. Echinacea-induced severe acute hepatitis with features of cholestatic autoimmune hepatitis. Eur J Intern Med. 2008 Mar;19(2):148.
  24. Maskatia ZK, Baker K. Hypereosinophilia associated with echinacea use. South Med J. 2010 Nov;103(11):1173-4.
  25. Bossaer JB, Odle BL. Probable etoposide interaction with Echinacea. J Diet Suppl. 2012 Jun;9(2):90-5.
  26. Karsch-Volk M, Barrett B, Kiefer D, et al. Echinacea for preventing and treating the common cold. Cochrane Database Syst Rev. 2014;2:Cd000530.
  27. Goey AK, Rosing H, Meijerman I, et al. The bioanalysis of the major Echinacea purpurea constituents dodeca-2E,4E,8Z,10E/Z-tetraenoic acid isobutylamides in human plasma using LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. Aug 1 2012;902:151-156.
  28. Pleschka S, Stein M, Schoop R, et al. Anti-viral properties and mode of action of standardized Echinacea purpurea extract against highly pathogenic avian influenza virus (H5N1, H7N7) and swine-origin H1N1 (S-OIV). Virol J. 2009;6:197.
  29. Goel V, Chang C, Slama JV, et al. Alkylamides of Echinacea purpurea stimulate alveolar macrophage function in normal rats. Int Immunopharmacol. Feb 2002;2(2-3):381-387.
  30. O’Neill W, McKee S, Clarke AF. Immunological and haematinic consequences of feeding a standardised Echinacea (Echinacea angustifolia) extract to healthy horses. Equine Vet J. May 2002;34(3):222-227.
  31. Haller J, Freund TF, Pelczer KG, et al. The anxiolytic potential and psychotropic side effects of an echinacea preparation in laboratory animals and healthy volunteers. Phytother Res. Jan 2013;27(1):54-61.
  32. Dogan Z, Ergul B, Sarikaya M, et al. The antioxidant effect of Echinacea angustifolia and Echinacea purpurea in rat colitis model induced by acetic acid. Bratisl Lek Listy. 2014;115(7):411-415.
  33. Pazyar N, Yaghoobi R, Rafiee E, et al. Skin wound healing and phytomedicine: a review. Skin Pharmacol Physiol. 2014;27(6):303-310.
  34. Zhai Z, Haney DM, Wu L, et al. Alcohol extract of Echinacea pallida reverses stress-delayed wound healing in mice. Phytomedicine. Jun 2009;16(6-7):669-678.
  35. Allan GM, Arroll B. Prevention and treatment of the common cold: making sense of the evidence. Cmaj. Feb 18 2014;186(3):190-199.
  36. Fashner J, Ericson K, Werner S. Treatment of the common cold in children and adults. Am Fam Physician. Jul 15 2012;86(2):153-159.
  37. Karsch-Volk M, Barrett B, Linde K. Echinacea for preventing and treating the common cold. Jama. Feb 10 2015;313(6):618-619.
  38. Raus K, Pleschka S, Klein P, et al. Effect of an Echinacea-Based Hot Drink Versus Oseltamivir in Influenza Treatment: A Randomized, Double-Blind, Double-Dummy, Multicenter, Noninferiority Clinical Trial. Curr Ther Res Clin Exp. Dec 2015;77:66-72.
  39. Dapas B, Dall’Acqua S, Bulla R, et al. Immunomodulation mediated by a herbal syrup containing a standardized Echinacea root extract: a pilot study in healthy human subjects on cytokine gene expression. Phytomedicine. Sep 25 2014;21(11):1406-1410.
  40. Whitehead MT, Martin TD, Scheett TP, et al. Running economy and maximal oxygen consumption after 4 weeks of oral Echinacea supplementation. J Strength Cond Res. Jul 2012;26(7):1928-1933.
  41. Baumann CW, Bond KL, Rupp JC, et al. Echinacea purpurea supplementation does not enhance VO2max in distance runners. J Strength Cond Res. May 2014;28(5):1367-1372.
  42. Tsai YL, Chiu CC, Yi-Fu Chen J, et al. Cytotoxic effects of Echinacea purpurea flower extracts and cichoric acid on human colon cancer cells through induction of apoptosis. J Ethnopharmacol. Oct 11 2012;143(3):914-919.
  43. Grappe F, Nance G, Coward L, et al. In vitro inhibitory effects of herbal supplements on tamoxifen and irinotecan metabolism. Drug Metabol Drug Interact. 2014;29(4):269-279.
  44. Molto J, Valle M, Miranda C, et al. Herb-drug interaction between Echinacea purpurea and etravirine in HIV-infected patients. Antimicrob Agents Chemother. Oct 2012;56(10):5328-5331.
  45. McCarty CA, Berg RL, Rottscheit CM, et al. The use of dietary supplements and their association with blood pressure in a large Midwestern cohort. BMC Complement Altern Med. 2013;13:339.
  46. Dante G, Bellei G, Neri I, et al. Herbal therapies in pregnancy: what works? Curr Opin Obstet Gynecol. Apr 2014;26(2):83-91.
  47. Zadoyan G, Fuhr U. Phenotyping studies to assess the effects of phytopharmaceuticals on in vivo activity of main human cytochrome p450 enzymes. Planta Med. Sep 2012;78(13):1428-1457.
  48. Gertsch J, Schoop R, Kuenzle U, et al. Echinacea alkylamides modulate TNF-alpha gene expression via cannabinoid receptor CB2 and multiple signal transduction pathways. FEBS Lett. Nov 19 2004;577(3):563-569.
  49. Amico AP, Terlizzi A, Damiani S, et al. Immunopharmacology of the main herbal supplements: a review. Endocr Metab Immune Disord Drug Targets. Dec 2013;13(4):283-288.
  50. Vetvicka V, Vetvickova J. Natural immunomodulators and their stimulation of immune reaction: true or false? Anticancer Res. May 2014;34(5):2275-2282.
  51. Pugh ND, Jackson CR, Pasco DS. Total bacterial load within Echinacea purpurea, determined using a new PCR-based quantification method, is correlated with LPS levels and in vitro macrophage activity. Planta Med. Jan 2013;79(1):9-14.
  52. Hermann R, von Richter O. Clinical evidence of herbal drugs as perpetrators of pharmacokinetic drug interactions. Planta Med. Sep 2012;78(13):1458-1477.
  53. Mooiman KD, Maas-Bakker RF, Moret EE, et al. Milk thistle’s active components silybin and isosilybin: novel inhibitors of PXR-mediated CYP3A4 induction. Drug Metab Dispos. Aug 2013;41(8):1494-1504.
  54. Huntley AL, Thompson Coon J, Ernst E. The safety of herbal medicinal products derived from Echinacea species: a systematic review. Drug Saf. 2005;28(5):387-400.
  55. Askeroglu U, Alleyne B, Guyuron B. Pharmaceutical and herbal products that may contribute to dry eyes. Plast Reconstr Surg. Jan 2013;131(1):159-167.
  56. Lawrenson JA, Walls T, Day AS. Echinacea-induced acute liver failure in a child. J Paediatr Child Health. Oct 2014;50(10):841.
  57. Gorski JC, Huang SM, Pinto A, et al. The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clin Pharmacol Ther. Jan 2004;75(1):89-100.
  58. Goey AK, Meijerman I, Rosing H, et al. The effect of Echinacea purpurea on the pharmacokinetics of docetaxel. Br J Clin Pharmacol. Sep 2013;76(3):467-474.
  59. Mooiman KD, Maas-Bakker RF, Hendrikx JJ, et al. The effect of complementary and alternative medicines on CYP3A4-mediated metabolism of three different substrates: 7-benzyloxy-4-trifluoromethyl-coumarin, midazolam and docetaxel. J Pharm Pharmacol. Jun 2014;66(6):865-874.
  60. Meng Q, Liu K. Pharmacokinetic interactions between herbal medicines and prescribed drugs: focus on drug metabolic enzymes and transporters. Curr Drug Metab. 2014;15(8):791-807.
  61. Gurley BJ, Swain A, Williams DK, et al. Gauging the clinical significance of P-glycoprotein-mediated herb-drug interactions: comparative effects of St. John’s wort, Echinacea, clarithromycin, and rifampin on digoxin pharmacokinetics. Mol Nutr Food Res. Jul 2008;52(7):772-779.
  62. Liu R, Tam TW, Mao J, et al. The effect of natural health products and traditional medicines on the activity of human hepatic microsomal-mediated metabolism of oseltamivir. J Pharm Pharm Sci. 2010;13(1):43-55.
  63. Oláh A, Szabó-Papp J, Soeberdt M, Knie U, Dähnhardt-Pfeiffer S, Abels C, Bíró T. Echinacea purpurea-derived alkylamides exhibit potent anti-inflammatory effects and alleviate clinical symptoms of atopic eczema. J Dermatol Sci. 2017 Oct;88(1):67-77.
  64. Kaymakamzade B, Karabudak R, Kurne AT, Nurlu G. Acute Disseminated Encephalomyelitis after Oral Therapy with Herbal Extracts: A Case Report. Balkan Med J. 2016 May;33(3):366-9.
  65. Gabranis I, Koufakis T, Papakrivos I, Batala S. Echinacea-associated acute cholestatic hepatitis. J Postgrad Med. 2015 Jul-Sep;61(3):211-2.
  66. Muthiah YD, Ong CE, Sulaiman SA, Ismail R. Inhibition of Human Cytochrome P450 2c8-catalyzed Amodiaquine N-desethylation: Effect of Five Traditionally and Commonly Used Herbs. Pharmacognosy Res. 2016 Oct-Dec;8(4):292-297.
  67. De Rosa N, Giampaolino P, Lavitola G, et al. Effect of Immunomodulatory Supplements Based on Echinacea Angustifolia and Echinacea Purpurea on the Posttreatment Relapse Incidence of Genital Condylomatosis: A Prospective Randomized Study. Biomed Res Int. 2019 Apr 11;2019:3548396.
  68. Aucoin M, Cooley K, Saunders PR, et al. The effect of Echinacea spp. on the prevention or treatment of COVID-19 and other respiratory tract infections in humans: A rapid review. Adv Integr Med. 2020 Dec;7(4):203-217.
  69. Haller J, Krecsak L, Zámbori J. Double-blind placebo controlled trial of the anxiolytic effects of a standardized Echinacea extract. Phytother Res. 2020 Mar;34(3):660-668.
  70. Sumer J, Keckeis K, Scanferla G, et al. Novel Echinacea formulations for the treatment of acute respiratory tract infections in adults-A randomized blinded controlled trial. Front Med (Lausanne). 2023 Apr 17;10:948787.
  71. Ogal M, Johnston SL, Klein P, Schoop R. Echinacea reduces antibiotic usage in children through respiratory tract infection prevention: a randomized, blinded, controlled clinical trial.  Eur J Med Res. 2021 Apr 8;26(1):33.
  72. Riemma G, Schettino MT, Munno GM, et al. Echinacea angustifolia and Echinacea purpurea Supplementation Combined with Vaginal Hyaluronic Acid to Boost the Remission of Cervical Low-Grade Squamous Intraepithelial Lesions (L-SILs): A Randomized Controlled Trial.  Medicina (Kaunas). 2022 May 9;58(5):646. 
  73. Lopresti AL, Smith SJ. An investigation into the anxiety-relieving and mood-enhancing effects of Echinacea angustifolia (EP107™): A randomised, double-blind, placebo-controlled study.  J Affect Disord. 2021 Oct 1;293:229-237. 
Email your questions and comments to [email protected].

Last Updated